Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
First Claim
1. A method comprising:
- administering dihydroergotamine, or a complex, chelate, salt, hydrate, polymorph, or ion pair thereof to a human suffering from migraine, cluster migraine, pediatric migraine, status migranosis or chronic daily headache;
wherein the dihydroergotamine, or a complex, chelate, salt, hydrate, polymorph, or ion pair thereof is administered at a rate such that a mean peak plasma concentration (Cmax) of 8-hydroxy dihydroergotamine is less than 10,000 pg/ml, and a mean time to Cmax (Tmax) of 8-hydroxy dihydroergotamine is less than 45 minutes, thereby achieving low adrenergic receptor binding and low side effects of one or more of nausea, chest tightness or pain, blood pressure excursions, or emesis.
1 Assignment
0 Petitions
Accused Products
Abstract
Pharmaceutical compositions containing dihydroergotamine (DHE) and methods in which DHE is administered to patients for treatment of migraine without side effects or adverse effects are disclosed. Methods for rapid treatment of migraine with DHE are disclosed comprising: dampening the peak plasma concentration (Cmax) and slightly delaying the peak such as to avoid activating the dopaminergic and adrenergic receptors, while achieving sufficient active binding to the serotonin receptors to provide relief from migraine symptoms within a timeframe that permits rapid resolution of migraine symptoms. Inhaler devices suitable for the methods are disclosed. Kits for practicing the methods of invention are disclosed.
273 Citations
32 Claims
-
1. A method comprising:
-
administering dihydroergotamine, or a complex, chelate, salt, hydrate, polymorph, or ion pair thereof to a human suffering from migraine, cluster migraine, pediatric migraine, status migranosis or chronic daily headache; wherein the dihydroergotamine, or a complex, chelate, salt, hydrate, polymorph, or ion pair thereof is administered at a rate such that a mean peak plasma concentration (Cmax) of 8-hydroxy dihydroergotamine is less than 10,000 pg/ml, and a mean time to Cmax (Tmax) of 8-hydroxy dihydroergotamine is less than 45 minutes, thereby achieving low adrenergic receptor binding and low side effects of one or more of nausea, chest tightness or pain, blood pressure excursions, or emesis. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)
-
-
17. A method comprising:
-
administering dihydroergotamine, or a complex, chelate, salt, hydrate, polymorph, or ion pair thereof to a human suffering from migraine, cluster migraine, pediatric migraine, status migranosis or chronic daily headache; wherein the dihydroergotamine, or a complex, chelate, salt, hydrate, polymorph, or ion pair thereof is administered at a rate such that a mean peak plasma concentration (Cmax) of 8-hydroxy dihydroergotamine is less than 10,000 pg/ml, and a mean time to Cmax (Tmax) of 8-hydroxy dihydroergotamine is less than 45 minutes; and wherein a total dose of the dihydroergotamine, or a complex, chelate, salt, hydrate, polymorph, or ion pair thereof that is administered ranges from 0.1 mg to 10.0 mg, and thereby achieving low adrenergic receptor binding and low side effects of one or more of nausea, chest tightness or pain, blood pressure excursions, or emesis. - View Dependent Claims (18)
-
-
19. A device comprising:
-
an inhaler; and one or more unit doses of a formulation comprising dihydroergotamine, or a complex, chelate, salt, hydrate, polymorph, or ion pair thereof to a human; wherein the inhaler is configured to administer each unit dose at a rate such that a mean peak plasma concentration (Cmax) of 8-hydroxy dihydroergotamine is less than 10,000 pg/ml, and a mean time to Cmax (Tmax) of 8-hydroxy dihydroergotamine is less than 45 minutes. - View Dependent Claims (20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)
-
Specification